In Brief Laleh Amiri-Kordestani named acting associate director for cardio-oncology at FDA OCE February 03, 2023Vol.49 No.05
Drugs & Targets Jaypirca receives FDA accelerated approval for R/R mantle cell lymphoma February 03, 2023Vol.49 No.05
Drugs & Targets Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval February 03, 2023Vol.49 No.05
Drugs & Targets RefleXion receives FDA clearance for SCINTIX biology-guided radiotherapy February 03, 2023Vol.49 No.05
Drugs & Targets FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma February 03, 2023Vol.49 No.05
FreeTrials & Tribulations Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization” January 27, 2023Vol.49 No.04By Mark J. Ratain and Garth W. Strohbehn
In Brief Grassley, Durbin, Tillis, Coons introduce legislation to strengthen coordination between Patent Office, FDA January 27, 2023Vol.49 No.04
Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
